This leaves a likely possibility that the enhanced sensitivity of TAA-specific CD4+ T cells (especially the Th1-type) to AICD as a primary cause for our observation of Type-1 deficiency in melanoma patients with AD (17, 40). This evidence concerns the gene CD4 and melanoma.